PubMed Health⌕ Search

Biomedical subjects

Lan Deng

Publications and source records attributed to Lan Deng.

7 recordsLinked to original sources
PubMed2006

[Structural modification of cyclovirobuxine D and their inhibition activity on lipid peroxidation].

AIM: To search for compounds through structural modification of cyclovirobuxine D, using 20 or 21-aminosteroids as lead compound for the treatment of cerebrovascular diseases with better lipid peroxidation inhibitory activity. METHODS: According to rational drug design principle, a series of cyclovirobuxine D analogues were prepared, and their bioactivities were tested. RESULTS: Four new compounds were obtained and confirmed by spectra. CONCLUSION: Lipid peroxidation inhibitory effects of cyclovirobuxine D analogues were tested by using TBA method. Some compounds showed better activity than that of cyclovirobuxine D.

Animals↗
PubMed2005

[Prodrug structural modifications of cyclovirobuxine D and their biological activity].

AIM: To search for compounds for the treatment of cardiovascular diseases through prodrug structural modifications of cyclovirobuxine D, a single efficient composition distilled from Box plant in China, which was used to treat angina and myocardial infarction. METHODS: According to prodrug design principle, a series of cyclovirobuxine D analogues were prepared, suc as succinate, phosphate and amino acid ester, and their biological activities were tested. RESULTS: Seven new compounds were obtained and confirmed with 1H NMR, MS, and element analysis. CONCLUSION: In pharmacology experiment, for treating arrhythmia induced by aconitine, succinate and amino acid ester of cyclovirobuxine D (I and VII) showed better activities than that of cyclovirobuxine D. The normal rhythm of the heart duration of I and VII were ( 11.53 +/- 7.62) min and (12.68 +/- 9.25) min, compared with 0.9% NaCl solution and cyclovirobuxine D, (2.36 +/- 1.68) min and (10.25 +/- 6.59) min (P < 0.01), respectively. Another pharmacology experiment, for treating arrhythmia induced by chloroform, the negative ratio of I and VII were 80% and 82%, compared with 0.9% NaCl solution and cyclovirobuxine D, 43% and 52% (P < 0.05), respectively. The difference between new compounds and cyclovirobuxine D was distinct.

Aconitine↗
PubMed2004

[Structural modification and bioactivity of cyclovirobuxine D].

AIM: To search for new compounds for the treatment of cardiovascular diseases by structural modification of cyclovirobuxine D. METHODS: According to rational drug design principle, a series of cyclovirobuxine D analogues were prepared, and their bioactivities were tested. RESULTS: Ten new compounds were syntheized and confirmed by spectra. CONCLUSION: Endurance lacking oxygen activity and antiarrhythmia effects of some analogues of cyclovirobuxine D were tested. Some compounds showed better activity than cyclovirobuxine D.

Anaerobic Threshold↗
PubMed2003

[Treatment of refractory leukemia by combined chemotherapy and halpotype lymphocytes infusion].

BACKGROUND & OBJECTIVE: The complete remission of refractory leukemia treated with conventional chemotherapy is below 50 percent. The high dose chemotherapy can cause more mortality of patients with refractory leukemia. Cytolysis of leukemia cells induced by halpotype lymphocytes was observed in vitro in our previous experiment. In order to improve the complete remission of refractory leukemia and decrease the complication of chemotherapy,the authors treated the patients with refractory leukemia by combined chemotherapy and halpotype lymphocytes infusion and to assess the therapeutic effects and the side effects of this modality. METHODS: Sixteen patients with refractory leukemia were treated by combined chemotherapy. Halpotype lymphocytes irradiated by 7.5 Gygamma radial were infused when patient's white cells count was at the lowest after the chemotherapy. A mean number of 1x10(8)/kg (range:0.8-1.2x10(8)/kg) of halpotype lymphocytes irradiated by 7.5 Gygamma radial was infused. The side effects of infusion of halpotype lymphocyte and completed remission rate were observed. RESULTS: Out of thirteen patients with refractory acute non-lymphocyte leukemia, eleven cases got complete remission and two partial remissions. Out of three patients with refractory acute lymphocyte leukemia, two got complete remission and one no reaction. The total remission rate was 81.2%. No severe side effects and no transfusion related graft versus host disease was observed. CONCLUSION: The results show that chemotherapy combined with 7.5 Gy irradiated halpotype lymphocyte infusion could improve the complete remission of refractory leukemia and decrease the complications caused by chemotherapy.

Adolescent↗
PubMed2002

[Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].

OBJECTIVE: To observe the effect of Ly49A transfected mouse spleen cells on graft versus host disease (GVHD) and graft versus leukemia (GVL) effect after haploidentical allogeneic bone marrow transplantation in mice. METHODS: Ly49A gene was transfected into spleen cells of C57BL/6 mice by retrovirus and the expression rate of Ly49A receptor was evaluated by flow cytometry. The murine model of haploidentical allogeneic acute GVHD was established by using C57BL/6(H - 2b) mouse as donor, and (BALB/c x C57BL/6) F1(H - 2d/b) (CB(6)F(1)) mouse as the recipient which was injected EL9611 cells before transplantation. After irradiation (TBI, (60)Co 10.5 Gy), the recipient received mixed graft of spleen cells and bone marrow cells to establish a GVHD model. The effects of Ly49A transfected spleen cells on GVHD and GVL post haploidentical allogeneic bone marrow transplantation were detected with this model. RESULTS: The expression rate of Ly49A receptor was (42.20 +/- 4.87)%, (18.67 +/- 2.48)% and (18.73 +/- 3.82)% for pLXSN-Ly49A, pLXSN transfected and untransfected spleen cells respectively. Among haploidentical allo-BMT (C57BL/6(H - 2b)-->CB6F1(H - 2d/b)) groups, the survival time was (7.80 +/- 3.36) days for irradiation group; (21.70 +/- 2.87) days for cyclophosphomide therapy group; (29.40 +/- 6.43) days for mixed bone marrow cells and spleen cells transplantation group; (29.10 +/- 7.39) days for mixed bone marrow cells and pLXSN transfected spleen cells transplantation group and (45.00 +/- 12.38) days for mixed bone marrow cells and Ly49A transfected spleen cells transplantation group, which was much longer than that of any other groups (P = 0.000). CONCLUSION: The Ly49A transfected spleen cell transplantation could alleviate GVHD and retain GVL effect in the acute GVHD model post haploidentical allo-BMT.

Animals↗